Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers

Addiction Biology

Volumn 18, Issue 5, 2013, Pages 872-881

  Bedi, Gillinder ^a   Cooper, Ziva D ^a   Haney, Margaret ^a  

^a Surgeons of Columbia University ^*  (United States)

Author keywords

Agonist treatment; dose effect profile; dronabinol; marijuana dependence; nabilone

Indexed keywords

CANNABIS; DRONABINOL; NABILONE; PLACEBO;

ADULT; ARTICLE; CANNABIS SMOKING; CAPSULE RATINGS FORM; CARDIOVASCULAR EFFECT; COGNITION; CONTROLLED STUDY; DIGIT SPAN TASK; DIGIT SYMBOL SUBSTITUTION TASK; DIVIDED ATTENTION TASK; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; MALE; MOOD; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; OUTPATIENT; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REPEATED ACQUISITION TASK; SELF REPORT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE;

AGONIST TREATMENT; DOSE-EFFECT PROFILE; DRONABINOL; MARIJUANA DEPENDENCE; NABILONE;

ADULT; AFFECT; ANALYSIS OF VARIANCE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CANNABINOID RECEPTOR AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HEART RATE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PLACEBOS; PSYCHOMOTOR PERFORMANCE; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; YOUNG ADULT;

EID: 84882628306     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2011.00427.x     Document Type: Article

References (43)

1. APA (1994) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
2. Bedi G, Foltin R, Gunderson E, Rabkin J, Hart C, Comer S, Vosburg S, Haney M, (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: A controlled laboratory study. Psychopharmacology 212: 675-686.
3. Ben Amar M, (2006) Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105: 1-25.
4. Brook JS, Zhang C, Brook DW, (2011) Developmental trajectories of marijuana use from adolescence to adulthood. Arch Pediatr Adolesc Med 165: 55-60.
5. Budney A, Roffman R, Stephens R, Walker D, (2007a) Marijuana dependence and its treatment. Addict Sci Clin Pract 4: 4-16.
6. Budney AJ, Moore BA, Rocha HL, Higgins ST, (2006) Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 74: 307-316. (Pubitemid 43807362)
7. Budney AJ, Vandrey RG, Hughes J, Moore BA, Bahrenburg B, (2007b) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86: 22-29. (Pubitemid 44708528)
8. Chen K, Kandel DB, Davies M, (1997) Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend 46: 53-67. (Pubitemid 27323018)
9. Folstein MF, Luria R, (1973) Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3: 479-486.
10. Fraser A, Meatherall R, (1989) Lack of interference by Nabilone in the EMIT® d.a.u cannabinoid assay, Abbott TDx® cannabinoid assay, and a sensitive TLC assay for delta-9-THC-carboxylic acid. J Anal Toxicol 13: 240. (Pubitemid 19182864)
11. Grassi MC, Enea D, Ferketich AK, Lu B, Pasquariello S, Nencini P, (2011) Effectiveness of varenicline for smoking cessation: A 1-year follow-up study. J Subst Abuse Treat 41: 64-70.
12. Haney M, (2002) Effects of smoked marijuana in healthy and HIV + marijuana smokers. J Clin Psychopharmacol 42: 34S-40S. (Pubitemid 35205044)
13. Haney M, (2007) Opioid antagonism of cannabinoid effects: differences between marijuana smokers and non-marijuana smokers. Neuropsychopharmacology 32: 1391-1403. (Pubitemid 46788849)
14. Haney M, (2008) Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14: 9-21.
15. Haney M, Hart C, Vosburg S, Comer S, Reed S, Foltin R, (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197: 157-168.
16. Haney M, Hart C, Vosburg S, Nasser J, Bennett A, Zubaran C, Foltin R, (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158-170. (Pubitemid 38068026)
17. Haney M, Rabkin J, Gunderson E, Foltin R, (2005) Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood. Psychopharmacology 181: 170-178. (Pubitemid 41440928)
18. Haney M, Ward A, Comer S, Foltin R, Fischman M, (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141: 385-394. (Pubitemid 29190007)
19. Haney M, Ward A, Comer S, Foltin R, Fischman M, (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141: 395-404. (Pubitemid 29190008)
20. Hart C, Haney M, Vosburg S, Comer S, Foltin R, (2005) Reinforcing effects of oral Delta-9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 181: 237-243. (Pubitemid 41492193)
21. Hart C, Ilan A, Gevins A, Gunderson E, Role K, Colley J, Foltin R, (2010) Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacol Biochem Behav 96: 333-341.
22. Hart C, van Gorp W, Haney M, Foltin R, Fischman M, (2001) Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25: 757-765. (Pubitemid 32995958)
23. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM, (2007) Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 32: 1220-1236. (Pubitemid 46497550)
24. Keppel G, (1991) Design and Analysis: A Researcher's Handbook, 4th edn. Upper Saddle River, NJ: Prentice Hall.
25. Lemberger L, Rowe H, (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18: 720-726.
26. Lemberger L, Rubin A, Wolen R, DeSante K, Rowe H, Forney R, Pence P, (1982) Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 9: 17-23. (Pubitemid 13127529)
27. Levin F, Mariani J, Brooks D, Pavlicova M, Cheng W, Nunes E, (2011) Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116: 142-150.
28. Lile J, Kelly T, Hays L, (2010) Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta-9-Tetrahydrocannabinol. Clin Neuropharmacol 33: 235-242.
29. Lile J, Kelly T, Hays L, (2011) Separate and combined effects of the cannabinoid agonists nabilone and delta9-THC in humans discriminating delta9-THC. Drug Alcohol Depend 116: 86-92.
30. McGilveray I, (2005) Pharmacokinetics of cannabinoids. Pain Res Manag 10 (Suppl. A): 15A-22A. (Pubitemid 44796349)
31. Mendelson J, Mello N, (1984) Reinforcing effects of oral delta-9 tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 83: 351-356. (Pubitemid 14057673)
32. MTP Research Group (2004) Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 72: 455-466.
33. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD, (2006) Behavioral therapy to augment oral naltrexone for opioid dependence: A ceiling on effectiveness? Am J Drug Alcohol Abuse 32: 503-517. (Pubitemid 44870988)
34. Parrott AC, Garnham NJ, Wesnes K, Pincock C, (1996) Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Hum Psychopharmacol 11: 391-400. (Pubitemid 26344702)
35. SAMSHA (2010) Results from the 2009 National Survey on Drug Use and Health. Rockville, MD: SAMSHA, Office of Applied Statistics.
36. Sheskin DJ, (2000) Handbook of Parametric and Nonparametric Statistical Procedures, 2nd edn. Boca Raton, FL: CRC Press LLC.
37. Stapleton J, Sutherland G, (2011) Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. Addiction 106: 824-832.
38. Threlkeld M, Parran T, Adelman C, Grey S, Yu J, (2006) Tramadol versus buprenorpine for the management of acute heroin withdrawal: A retrospective matched cohort control study. Am J Addict 15: 186-191.
39. United Nations Office on Drugs and Crime (2007) 2007 World Drug Report. Vienna, Austria: UNODC.
40. Vandrey RG, Budney AJ, Hughes JR, Liguori A, (2008) A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 92: 48-54. (Pubitemid 350213236)
41. Ware M, St Arnaud-Trempe E, (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105: 494-503.
42. Wesnes K, Annas P, Edgar C, Deeprose C, Karlsten R, Philipp A, Kalliomaki J, Segerdahl M, (2010) Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol 24: 1659-1669.
43. Zobel I, Kech S, van Calker D, Dykierek P, Berger M, Schneibel R, Schramm E, (2011) Long-term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patients. Acta Psychiatr Scand 123: 276-282.